Andere talen argenx SE

Aandelen

ARGX

NL0010832176

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Euronext Bruxelles Andere beurzen 17:35:18 24-06-2025			Nabeurs 19:21:48
488,40 ^EUR	+4,81%		488,80	+0,08%

23/06	Argenx krijgt Europese goedkeuring voor Vyvgart als injectie tegen CIDP	AM
23/06	Argenx Krijgt Goedkeuring in EU voor Monotherapie bij Zeldzame Auto-immuunziekte	MT

Andere talen

Washington cogne d'abord et discute ensuite	23/06
Bourse : Kering sort de l'Euro Stoxx 50, Filosa débarque chez Stellantis, Carmat au bord du gouffre	23/06
Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	23/06
Sector Update: Health Care Stocks Softer in Afternoon Trading	20/06
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	20/06
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	20/06
Argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	20/06
FTSE MIB, CAC40, DAX, SMI: 9 indici, 9 climi diversi	20/06
Deux semaines de réflexion	20/06
Avis d'analystes du jour : LVMH se fait raboter, Hochtief et Barclays ont de nouveaux fans	20/06
Argenx : argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	20/06
Índices: IBEX-35, CAC40, DAX, SMI… 9 índices muy dispares	19/06
DAX, CAC, SMI, IBEX… 9 Indizes, 9 Stimmungen	17/06
CAC40, DAX, SMI, IBEX… 9 indices, 9 ambiances	17/06
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	16/06
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	11/06
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	11/06
Un mini-deal en attendant l'inflation américaine	11/06
Bourse : le F-35 dans le dur, Zara déçoit et Publicis chipe un Mars à WPP	11/06
Argenx : argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	11/06
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	11/06
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	11/06
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	11/06
Argenx : argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference	03/06
Argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference	03/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

ArgenX stuwt Bel20 omhoog na goed nieuws voor Vyvgart

24 juni 2024 om 22:11 uur